Shanghai DiaKete Biomedical Technology

Shanghai DiaKete Biomedical Technology is a clinical-stage biotechnology company focused on the development of innovative therapies for metabolic disorders, including type 2 diabetes and obesity. The company leverages a specialized peptide drug discovery platform to create long-acting incretin-based treatments such as GLP-1 receptor agonists and multi-target agonists. Its lead program, DK001, is a long-acting GLP-1 receptor agonist currently in clinical development, designed to offer improved glycemic control and weight loss. DiaKete aims to provide high-quality, accessible therapeutic solutions to address the significant unmet needs in the global metabolic disease market. Headquartered in Shanghai, the company is backed by leading venture capital firms and led by a team with extensive experience in pharmaceutical R&D.